4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-043553
Chief Executive Officer sold 25,000 shares at an average $75.91 ($1,897,747)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Option exercise | +8,333 | $12.57 | $104,746 | 298,612 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Option exercise | +16,667 | $16.21 | $270,172 | 315,279 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Sale | −6,933 | $75.64 | $524,402 | 308,346 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Sale | −700 | $76.37 | $53,461 | 307,646 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Sale | −700 | $77.79 | $54,455 | 306,946 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Sale | −12,759 | $75.73 | $966,265 | 294,187 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Sale | −3,308 | $76.29 | $252,382 | 290,879 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Sale | −600 | $77.97 | $46,783 | 290,279 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Option exercise · Stock Option (Right to Buy) | −8,333 | 0 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2022-07-27 | Option exercise · Stock Option (Right to Buy) | −16,667 | 83,333 | D | ||
| Open-market sales · 25,000 sh · avg $75.91 · $1,897,747 | |||||||
Loading xslF345X03/doc4.xml…